发明申请
US20150366843A1 Endothelin Single Nucleotide Polymorphisms and Methods of Predicting B-Adrenergic Receptor Targeting Agent Efficacy
审中-公开
内皮素单核苷酸多态性和预测B肾上腺素能受体靶向剂功效的方法
- 专利标题： Endothelin Single Nucleotide Polymorphisms and Methods of Predicting B-Adrenergic Receptor Targeting Agent Efficacy
- 专利标题（中）： 内皮素单核苷酸多态性和预测B肾上腺素能受体靶向剂功效的方法
-
申请号： US14746362申请日： 2015-06-22
-
公开(公告)号： US20150366843A1公开(公告)日： 2015-12-24
- 发明人: Matthew R.G. Taylor , Luisa Mestroni
- 申请人： The Regents of the University of Colorado, A Body Corporate
- 主分类号： A61K31/4045
- IPC分类号： A61K31/4045
摘要：
The present invention concerns the use of methods for evaluating β-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a β-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a β-blocker. Accordingly, methods of treatment are also described.
公开/授权文献
信息查询
IPC分类:
